RT Journal Article
T1 A Modified Progressive Supranuclear Palsy Rating Scale.
A1 Grötsch, Marie-Therese
A1 Respondek, Gesine
A1 Colosimo, Carlo
A1 Compta, Yaroslau
A1 Corvol, Jean Christophe
A1 Ferreira, Joaquim
A1 Huber, Meret Koroni
A1 Klietz, Martin
A1 Krey, Lea F M
A1 Levin, Johannes
A1 Jecmenica-Lukic, Milica
A1 Macías-García, Daniel
A1 Meissner, Wassilios G
A1 Mir, Pablo
A1 Morris, Huw
A1 Nilsson, Christer
A1 Rowe, James B
A1 Seppi, Klaus
A1 Stamelou, Maria
A1 van-Swieten, John C
A1 Wenning, Gregor
A1 Del-Ser, Teodoro
A1 Golbe, Lawrence I
A1 Höglinger, Günter U
K1 clinical meaningfulness
K1 progressive supranuclear palsy
K1 rating scale
K1 sensitivity to change
AB The Progressive Supranuclear Palsy Rating Scale is a prospectively validated physician-rated measure of disease severity for progressive supranuclear palsy. We hypothesized that, according to experts' opinion, individual scores of items would differ in relevance for patients' quality of life, functionality in daily living, and mortality. Thus, changes in the score may not equate to clinically meaningful changes in the patient's status. The aim of this work was to establish a condensed modified version of the scale focusing on meaningful disease milestones. Sixteen movement disorders experts evaluated each scale item for its capacity to capture disease milestones (0 = no, 1 = moderate, 2 = severe milestone). Items not capturing severe milestones were eliminated. Remaining items were recalibrated in proportion to milestone severity by collapsing across response categories that yielded identical milestone severity grades. Items with low sensitivity to change were eliminated, based on power calculations using longitudinal 12-month follow-up data from 86 patients with possible or probable progressive supranuclear palsy. The modified scale retained 14 items (yielding 0-2 points each). The items were rated as functionally relevant to disease milestones with comparable severity. The modified scale was sensitive to change over 6 and 12 months and of similar power for clinical trials of disease-modifying therapy as the original scale (achieving 80% power for two-sample t test to detect a 50% slowing with n = 41 and 25% slowing with n = 159 at 12 months). The modified Progressive Supranuclear Palsy Rating Scale may serve as a clinimetrically sound scale to monitor disease progression in clinical trials and routine. © 2021 International Parkinson and Movement Disorder Society.
PB John Wiley & Sons, Inc.
YR 2021
FD 2021-05-15
LK http://hdl.handle.net/10668/17066
UL http://hdl.handle.net/10668/17066
LA en
NO Grötsch MT, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, et al. A Modified Progressive Supranuclear Palsy Rating Scale. Mov Disord. 2021 May;36(5):1203-1215.
DS RISalud
RD Apr 5, 2025